Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma

Cancer

Volumn 89, Issue 10, 2000, Pages 2122-2130

  Kushner, Brian H ^a   Heller, Glenn ^a   Kramer, Kim ^a   Cheung, Nai Kong V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Dose intensive chemotherapy; Granulocyte colony stimulating factor (G CSF); Neuroblastoma

Indexed keywords

ALKYLATING AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CHEMOPROPHYLAXIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEVER; HUMAN; INFECTION; MAJOR CLINICAL STUDY; NEUROBLASTOMA; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW NEOPLASMS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEVER; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INFANT; NEUROBLASTOMA; NEUTROPENIA; REMISSION INDUCTION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0034669424     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20001115)89:10<2122::AID-CNCR13>3.0.CO;2-K     Document Type: Article

References (38)

1. Hematopoietic growth factors - Not whether, but when and where
2. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
3. Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines
4. Effect of granulocyte colony-stimulating factor chemotherapy-induced neutropenia in children with cancer
5. Assessment of the value of treatment with granulocyte colony-stimulating factor in children with acute lymphoblastic leukemia: A randomized clinical trial
6. 2/day of G-CSF in pediatric patients with neutropenia induced by chemotherapy
7. Prophylactic administration of granulocyte colony-stimulating factor (filgrastim) after conventional chemotherapy in children with cancer
8. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia
9. Granulocyte colony-stimulating factor in established febrile neutropenia: A randomized study of pediatric patients
10. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia
11. Randomized trial of r-metHu granulocyte colony-stimulating factor in an intensive treatment for T-cell leukemia and advanced-stage lymphoblastic lymphoma of childhood: A Pediatric Oncology Group pilot study
12. Cost-minimization analysis of prophylactic granulocyte colony-stimulating factor after induction chemotherapy in children with non-Hodgkin's lymphoma
13. Granulocyte colony-stimulating factor ameliorates toxicity of intensification chemotherapy for acute lymphoblastic leukemia
14. A case-control retrospective study of the efficacy of granulocyte-colony-stimulating factor in children with neuroblastoma
15. Use of granulocyte colony stimulating factor to reduce the toxicity of Super-VAC chemotherapy in advanced solid tumours in childhood
16. Prospective and randomized comparison of early versus delayed prophylactic administration of granulocyte colony-stimulating factor (filgrastim) in children with cancer
17. An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma
18. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age
19. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment
20. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis
21. Granulocyte-macrophage-colony stimulating factor for prevention of neutropenia and infections in children and adolescents with solid tumors
22. Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy
23. Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfomide, carboplatin, and etoposide chemotherapy
24. Granulocyte-macrophage colony-stimulating factor in association with high-dose chemotherapy (VETOPEC) for childhood solid tumors: A report from the Australia and New Zealand Children's Cancer Study Group
25. A phase I dose escalation of combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with neuroblastoma
26. Human granulocyte-macrophage colony-stimulating factor is a growth factor active on a variety of cell types of nonhemopoietic origin
27. Nonhematopoietic tumor cells express functional GM-CSF receptors
28. Various human hematopoietic growth factors (interleukein-3, GM-CSF, G-CSF) stimulate clonal growth of nonhematopoietic tumor cells
29. Human granulocyte colony-stimulating factor: Biologic activities and receptor characterization on hematopoietic cells and small cell lung cancer cell lines
30. Safety of early hospital discharge of selected ferbile children and adolescents with cancer with prolonged neutropenia
31. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma
32. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma
33. Hematopoietic stem cell depletion by restorative growth factor regimens during repeated high-dose cyclophosphamide therapy
34. Cyclophosphamide, doxorubicin, vincristine, prednisone dose-intensification with granulocyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation
35. Granulocyte colony-stimulating factor enhances bone marrow stem cell damage caused by repeated administration of cytotoxic agents
36. Does a clinical trial warrant an economic analysis?
37. Neuroblastoma and treatment-related myelodysplasia/leukemia: The Memorial Sloan-Kettering experience and a literature review